107 SPRING STREET, SEATTLE, WA
Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Investor Presentation
Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Elects Directors at 2026 Annual Meeting
Other Events
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Delisting Amendment